Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prospective Randomized Open Multicenter Study of Cognitive Effects of Endocrine Therapy in Non-metastatic Breast Cancer
2008-003620-32Phase 3Completed
- Sponsor
- Centre Oscar Lambret
- Start
- Jul 2008
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of tamoxifen, exemestane, letrozole and anastrozole in breast cancer (4 arms), sponsored by Centre Oscar Lambret. Primary endpoint: Change in verbal episodic memory at 6 months. Started Jul 2008; status: completed.
02
Drugs
tamoxifenexemestaneletrozoleanastrozole
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2008-003620-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-003620-32.